Inositec ^Companies

Inositec is a biotech company that was founded in 2015 as a spin-off of ETH Zurich. They specialize in developing a treatment for soft tissue calcification disorders using their proprietary Inositune platform of inositol phosphate (IP6) analogs. Their main focus is on addressing vascular and renal calcification disorders, including orphan indications.